D L Carlson Investment Group Inc. grew its stake in Novartis AG (NYSE:NVS) by 110.8% during the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 73,080 shares of the company’s stock after purchasing an additional 38,410 shares during the period. Novartis AG comprises about 1.8% of D L Carlson Investment Group Inc.’s investment portfolio, making the stock its 8th biggest position. D L Carlson Investment Group Inc.’s holdings in Novartis AG were worth $6,100,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
Several other institutional investors have also modified their holdings of NVS. Primecap Management Co. CA lifted its holdings in Novartis AG by 2.1% during the 1st quarter. Primecap Management Co. CA now owns 21,693,804 shares of the company’s stock valued at $1,611,199,000 after purchasing an additional 446,976 shares during the last quarter. Wells Fargo & Company MN raised its stake in shares of Novartis AG by 12.2% in the first quarter. Wells Fargo & Company MN now owns 9,100,801 shares of the company’s stock worth $675,917,000 after acquiring an additional 988,301 shares during the last quarter. Parnassus Investments CA raised its stake in shares of Novartis AG by 89.4% in the first quarter. Parnassus Investments CA now owns 8,173,974 shares of the company’s stock worth $593,720,000 after acquiring an additional 3,858,632 shares during the last quarter. Bank of America Corp DE raised its stake in shares of Novartis AG by 7.5% in the first quarter. Bank of America Corp DE now owns 7,328,730 shares of the company’s stock worth $544,304,000 after acquiring an additional 508,435 shares during the last quarter. Finally, Fisher Asset Management LLC raised its stake in shares of Novartis AG by 6.3% in the second quarter. Fisher Asset Management LLC now owns 6,505,935 shares of the company’s stock worth $543,050,000 after acquiring an additional 384,262 shares during the last quarter. Institutional investors and hedge funds own 10.98% of the company’s stock.
COPYRIGHT VIOLATION WARNING: “D L Carlson Investment Group Inc. Purchases 38,410 Shares of Novartis AG (NYSE:NVS)” was originally published by The Ledger Gazette and is the property of of The Ledger Gazette. If you are viewing this piece of content on another website, it was copied illegally and republished in violation of international copyright & trademark legislation. The original version of this piece of content can be accessed at https://ledgergazette.com/2017/09/17/d-l-carlson-investment-group-inc-grows-stake-in-novartis-ag-nvs.html.
In other news, major shareholder Bioventures Ltd Novartis purchased 266,667 shares of the business’s stock in a transaction on Wednesday, July 5th. The stock was acquired at an average price of $15.00 per share, for a total transaction of $4,000,005.00. The acquisition was disclosed in a document filed with the SEC, which is available through this link. Company insiders own 0.01% of the company’s stock.
Novartis AG (NVS) traded down 0.29% during trading on Friday, hitting $85.58. 1,933,504 shares of the company traded hands. Novartis AG has a 12-month low of $66.93 and a 12-month high of $86.90. The company has a market capitalization of $200.50 billion, a P/E ratio of 31.24 and a beta of 0.74. The stock has a 50 day moving average price of $84.27 and a 200 day moving average price of $80.30.
Novartis AG (NYSE:NVS) last released its quarterly earnings results on Tuesday, July 18th. The company reported $1.22 earnings per share for the quarter, beating the consensus estimate of $1.16 by $0.06. The business had revenue of $12.24 billion during the quarter, compared to analysts’ expectations of $12.20 billion. Novartis AG had a return on equity of 15.51% and a net margin of 13.52%. The firm’s revenue for the quarter was down 1.8% compared to the same quarter last year. During the same quarter last year, the business posted $1.23 EPS. On average, equities analysts anticipate that Novartis AG will post $4.75 earnings per share for the current year.
Several equities research analysts have recently commented on NVS shares. Zacks Investment Research cut shares of Novartis AG from a “hold” rating to a “sell” rating in a report on Monday, July 10th. BidaskClub upgraded shares of Novartis AG from a “sell” rating to a “hold” rating in a report on Saturday, August 19th. J P Morgan Chase & Co reiterated a “neutral” rating on shares of Novartis AG in a report on Thursday, June 8th. Morgan Stanley upgraded shares of Novartis AG from an “underweight” rating to an “overweight” rating in a report on Wednesday, July 26th. Finally, Cowen and Company set a $77.00 price objective on shares of Novartis AG and gave the stock a “hold” rating in a research report on Tuesday, July 11th. Three research analysts have rated the stock with a sell rating, ten have issued a hold rating and six have issued a buy rating to the company. Novartis AG presently has an average rating of “Hold” and a consensus price target of $83.56.
Novartis AG Company Profile
Novartis AG is a holding company, which provides healthcare solutions. The Company is engaged in the research, development, manufacturing and marketing of a range of healthcare products led by pharmaceuticals. The Company’s segments include Innovative Medicines, Sandoz, Alcon and Corporate activities.
Receive News & Ratings for Novartis AG Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novartis AG and related companies with MarketBeat.com's FREE daily email newsletter.